Erythropoietin doping in cycling: Lack of evidence for efficacy and a negative risk-benefit

British Journal of Clinical Pharmacology

Volumn 75, Issue 6, 2013, Pages 1406-1421

  Heuberger, Jules A A C ^a   Cohen Tervaert, Joost M ^a   Schepers, Femke M L ^a   Vliegenthart, Adriaan D B ^a   Rotmans, Joris I ^b   Daniels, Johannes M A ^c   Burggraaf, Jacobus ^d   Cohen, Adam F ^b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Athletic performance; Doping in sports; Erythropoietin; Recombinant proteins

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANALYTICAL PARAMETERS; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CYCLING; DOPING; DRUG EFFICACY; ECONOMIC ASPECT; ENDURANCE; HEMATOLOGY; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; LACTATE THRESHOLD; LACTATE TURN POINT; MALPRACTICE; MAXIMAL OXYGEN UPTAKE; MEDICAL LITERATURE; NONHUMAN; OXYGEN CONSUMPTION; PHYSIOLOGY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RISK BENEFIT ANALYSIS;

ATHLETIC PERFORMANCE; BICYCLING; DOPING IN SPORTS; ERYTHROPOIETIN; HUMANS; PHYSICAL ENDURANCE; RISK ASSESSMENT; RISK FACTORS;

EID: 84878120349     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12034     Document Type: Article

References (164)

1. United States Anti-Doping Agency. Reasoned decision of the united states anti-doping agency on disqualification and ineligibility - united states anti-doping agency, claimant, v. lance armstrong, Respondent. 2012.
2. Sackmann E. Biological membranes architecture and function. In: Handbook of Biological Physics, eds Lipowsky R and Sackmann E Amsterdam: Elsevier, 1995; 1-62.
3. Ratcliffe P, Eckardt K, Bauer C. Hypoxia, erythropoietin gene expression, and erythropoiesis. In: Handbook of Physiology-Environmental Physiology, eds Fregly MJ and Blatteis CM New York: Published for the American Physiological Society by Oxford University Press, 1996; 1125-1153.
4. Carnot P, DeFlandre C. Sur l'activite hemopoietique de serum au cours de la regeneration du sang. C R Acad Sci (Paris) 1906; 143: 384-386.
5. Imai N, Kawamura A, Higuchi M, Oh-Eda M, Orita T, Kawaguchi T, Ochi N. Physicochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J Biochem 1990; 107: 352-359.
6. Recny MA, Scoble HA, Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 1987; 262: 17156-17163.
7. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood 1991; 77: 2583-2590.
8. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248: 378-381.
9. Gobert S, Duprez V, Lacombe C, Gisselbrecht S, Mayeux P. The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells. Eur J Biochem 1995; 234: 75-83.
10. Miura Y, Miura O, Ihle JN, Aoki N. Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. J Biol Chem 1994; 269: 29962-29969.
11. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol 2008; 36: 1573-1584.
12. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999; 283: 990-993.
13. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. 1957. J Am Soc Nephrol 2000; 11: 589-590.
14. Kuratowska Z, Lewartowski B, Michalski E. Studies on the production of erythropoietin by isolated organs. Blood 1961; 18: 527-534.
15. Fisher JW, Koury S, Ducey T, Mendel S. Erythropoietin production by interstitial cells of hypoxic monkey kidneys. Br J Haematol 1996; 95: 27-32.
16. Koury ST, Bondurant MC, Koury MJ, Semenza GL. Localization of cells producing erythropoietin in murine liver by in situ hybridization. Blood 1991; 77: 2497-2503.
17. Cotes PM, Dore CJ, Yin JA, Lewis SM, Messinezy M, Pearson TC, Reid C. Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis. N Engl J Med 1986; 315: 283-287.
18. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15: 551-578.
19. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993; 90: 4304-4308.
20. Haase VH. Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 2010; 299: F1-13.
21. Bruegge K, Jelkmann W, Metzen E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem 2007; 14: 1853-1862.
22. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003; 228: 1-14.
23. Imagawa S, Nakano Y, Obara N, Suzuki N, Doi T, Kodama T, Nagasawa T, Yamamoto M. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J 2003; 17: 1742-1744.
24. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood 1989; 74: 645-651.
25. Koury MJ, Sawyer ST, Bondurant MC. Splenic erythroblasts in anemia-inducing Friend disease: a source of cells for studies of erythropoietin-mediated differentiation. J Cell Physiol 1984; 121: 526-532.
26. Eckardt KU, Boutellier U, Kurtz A, Schopen M, Koller EA, Bauer C. Rate of erythropoietin formation in humans in response to acute hypobaric hypoxia. J Appl Physiol 1989; 66: 1785-1788.
27. Goldwasser E, Kung CK, Eliason J. On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem 1974; 249: 4202-4206.
28. Dinkelaar RB, Engels EY, Hart AA, Schoemaker LP, Bosch E, Chamuleau RA. Metabolic studies on erythropoietin (EP): II. The role of liver and kidney in the metabolism of Ep. Exp Hematol 1981; 9: 796-803.
29. Steinberg SE, Garcia JF, Matzke GR, Mladenovic J. Erythropoietin kinetics in rats: generation and clearance. Blood 1986; 67: 646-649.
30. Nalbant D, Saleh M, Goldman FD, Widness JA, Veng-Pedersen P. Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. J Pharmacol Exp Ther 2010; 333: 528-532.
31. Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, Veng-Pedersen P. Change in erythropoietin pharmacokinetics following hematopoietic transplantation. Clin Pharmacol Ther 2007; 81: 873-879.
32. Stohlman F Jr. Observations on the physiology of erythropoietin and its role in the regulation of red cell production. Ann NY Acad Sci 1959; 77: 710-724.
33. Alexanian R. Erythropoietin excretion in bone marrow failure and hemolytic anemia. J Lab Clin Med 1973; 82: 438-445.
34. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985; 82: 7580-7584.
35. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-810.
36. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78.
37. Sasaki H, Bothner B, Dell A, Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 1987; 262: 12059-12076.
38. Egrie J, Eschbach JW, Adamson JW, McGuire T. Pharmacokinetics of recombinant human erythropoietin administered to hemodialysis (HD) patients. Kidney Int 1988; 33: 262.
39. European Medicines Agency. NeoRecormon, INN-Epoetin beta. 2004.
40. European Medicines Agency. Dynepo is epoetin delta. 2002.
41. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003; 21: 414-421.
42. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005; 4: 436-440.
43. World Anti-Doping Agency. [online]. Available at http://www.wada-ama.org/en (last accessed June 2012).
44. Pate RR, Kriska A. Physiological basis of the sex difference in cardiorespiratory endurance. Sports Med 1984; 1: 87-98.
45. Joyner MJ, Coyle EF. Endurance exercise performance: the physiology of champions. J Physiol 2008; 586: 35-44.
46. Coyle EF. Physiological determinants of endurance exercise performance. J Sci Med Sport 1999; 2: 181-189.
47. Jones AM. A five year physiological case study of an Olympic runner. Br J Sports Med 1998; 32: 39-43.
48. Pollock ML. Submaximal and maximal working capacity of elite distance runners. Part I: cardiorespiratory aspects. Ann NY Acad Sci 1977; 301: 310-322.
49. Saltin B, Astrand PO. Maximal oxygen uptake in athletes. J Appl Physiol 1967; 23: 353-358.
50. Enoksen E, Shalfawi SA, Tonnessen E. The effect of high- vs. low-intensity training on aerobic capacity in well-trained male middle-distance runners. J Strength Cond Res 2011; 25: 812-818.
51. Helgerud J, Engen LC, Wisloff U, Hoff J. Aerobic endurance training improves soccer performance. Med Sci Sports Exerc 2001; 33: 1925-1931.
52. Davis HA, Bassett J, Hughes P, Gass GC. Anaerobic threshold and lactate turnpoint. Eur J Appl Physiol Occup Physiol 1983; 50: 383-392.
53. Bassett DR Jr, Howley ET. Limiting factors for maximum oxygen uptake and determinants of endurance performance. Med Sci Sports Exerc 2000; 32: 70-84.
54. Heinicke K, Wolfarth B, Winchenbach P, Biermann B, Schmid A, Huber G, Friedmann B, Schmidt W. Blood volume and hemoglobin mass in elite athletes of different disciplines. Int J Sports Med 2001; 22: 504-512.
55. Wagner PD. New ideas on limitations to VO2max. Exerc Sport Sci Rev 2000; 28: 10-14.
56. Convertino VA. Blood volume: its adaptation to endurance training. Med Sci Sports Exerc 1991; 23: 1338-1348.
57. Buick FJ, Gledhill N, Froese AB, Spriet L, Meyers EC. Effect of induced erythrocythemia on aerobic work capacity. J Appl Physiol 1980; 48: 636-642.
58. Brien AJ, Simon TL. The effects of red blood cell infusion on 10-km race time. JAMA 1987; 257: 2761-2765.
59. Ekblom B. Blood doping and erythropoietin. The effects of variation in hemoglobin concentration and other related factors on physical performance. Am J Sports Med 1996; 24: S40-S42.
60. Celsing F, Svedenhag J, Pihlstedt P, Ekblom B. Effects of anaemia and stepwise-induced polycythaemia on maximal aerobic power in individuals with high and low haemoglobin concentrations 1. Acta Physiol Scand 1987; 129: 47-54.
61. Sjodin B, Svedenhag J. Applied physiology of marathon running. Sports Med 1985; 2: 83-99.
62. Londeree BR. The use of laboratory test results with long distance runners. Sports Med 1986; 3: 201-213.
63. Lucia A, Hoyos J, Santalla A, Perez M, Chicharro JL. Kinetics of VO(2) in professional cyclists. Med Sci Sports Exerc 2002; 34: 320-325.
64. Lucia A, Pardo J, Durantez A, Hoyos J, Chicharro JL. Physiological differences between professional and elite road cyclists. Int J Sports Med 1998; 19: 342-348.
65. Coyle EF, Coggan AR, Hopper MK, Walters TJ. Determinants of endurance in well-trained cyclists. J Appl Physiol 1988; 64: 2622-2630.
66. Wilber RL, Zawadzki KM, Kearney JT, Shannon MP, Disalvo D. Physiological profiles of elite off-road and road cyclists. Med Sci Sports Exerc 1997; 29: 1090-1094.
67. Coyle EF, Feltner ME, Kautz SA, Hamilton MT, Montain SJ, Baylor AM, Abraham LD, Petrek GW. Physiological and biomechanical factors associated with elite endurance cycling performance. Med Sci Sports Exerc 1991; 23: 93-107.
68. Jones AM. The physiology of the Wolrd Record Holder for the Women's Marathon. Int J Sports Sci Coach 2006; 1: 101-116.
69. Coyle EF. Improved muscular efficiency displayed as Tour de France champion matures. J Appl Physiol 2005; 98: 2191-2196.
70. Helgerud J, Hoydal K, Wang E, Karlsen T, Berg P, Bjerkaas M, Simonsen T, Helgesen C, Hjorth N, Bach R, Hoff J. Aerobic high-intensity intervals improve VO2max more than moderate training. Med Sci Sports Exerc 2007; 39: 665-671.
71. Esfarjani F, Laursen PB. Manipulating high-intensity interval training: effects on VO2max, the lactate threshold and 3000m running performance in moderately trained males. J Sci Med Sport 2007; 10: 27-35.
72. Billat VL, Flechet B, Petit B, Muriaux G, Koralsztein JP. Interval training at VO2max: effects on aerobic performance and overtraining markers. Med Sci Sports Exerc 1999; 31: 156-163.
73. Weston AR, Myburgh KH, Lindsay FH, Dennis SC, Noakes TD, Hawley JA. Skeletal muscle buffering capacity and endurance performance after high-intensity interval training by well-trained cyclists. Eur J Appl Physiol Occup Physiol 1997; 75: 7-13.
74. Chicharro JL, Hoyos J, Lucia A. Effects of endurance training on the isocapnic buffering and hypocapnic hyperventilation phases in professional cyclists. Br J Sports Med 2000; 34: 450-455.
75. Nevill AM, Jobson SA, Palmer GS, Olds TS. Scaling maximal oxygen uptake to predict cycling time-trial performance in the field: a non-linear approach. Eur J Appl Physiol 2005; 94: 705-710.
76. Padilla S, Mujika I, Angulo F, Goiriena JJ. Scientific approach to the 1-h cycling world record: a case study. J Appl Physiol 2000; 89: 1522-1527.
77. Jeukendrup AE, Craig NP, Hawley JA. The bioenergetics of World Class Cycling. J Sci Med Sport 2000; 3: 414-433.
78. Lucia A, Hoyos J, Perez M, Santalla A, Chicharro JL. Inverse relationship between VO2max and economy/efficiency in world-class cyclists. Med Sci Sports Exerc 2002; 34: 2079-2084.
79. Ingham SA, Whyte GP, Pedlar C, Bailey DM, Dunman N, Nevill AM. Determinants of 800-m and 1500-m running performance using allometric models. Med Sci Sports Exerc 2008; 40: 345-350.
80. di Prampero PE, Atchou G, Bruckner JC, Moia C. The energetics of endurance running. Eur J Appl Physiol Occup Physiol 1986; 55: 259-266.
81. Coyle EF, Martin WH III, Bloomfield SA, Lowry OH, Holloszy JO. Effects of detraining on responses to submaximal exercise. J Appl Physiol 1985; 59: 853-859.
82. Kumagai S, Tanaka K, Matsuura Y, Matsuzaka A, Hirakoba K, Asano K. Relationships of the anaerobic threshold with the 5km, 10km, and 10 mile races. Eur J Appl Physiol Occup Physiol 1982; 49: 13-23.
83. Lucia A, Hoyos J, Perez M, Chicharro JL. Heart rate and performance parameters in elite cyclists: a longitudinal study. Med Sci Sports Exerc 2000; 32: 1777-1782.
84. Andersen P, Henriksson J. Capillary supply of the quadriceps femoris muscle of man: adaptive response to exercise. J Physiol 1977; 270: 677-690.
85. Tesch PA, Wright JE. Recovery from short term intense exercise: its relation to capillary supply and blood lactate concentration. Eur J Appl Physiol Occup Physiol 1983; 52: 98-103.
86. Saltin B. Hemodynamic adaptations to exercise. Am J Cardiol 1985; 55: 42D-47.
87. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986; 60: 2020-2027.
88. Sjodin B, Jacobs I. Onset of blood lactate accumulation and marathon running performance. Int J Sports Med 1981; 2: 23-26.
89. Lucia A, Hoyos J, Chicharro JL. Physiology of professional road cycling. Sports Med 2001; 31: 325-337.
90. Padilla S, Mujika I, Santisteban J, Impellizzeri FM, Goiriena JJ. Exercise intensity and load during uphill cycling in professional 3-week races. Eur J Appl Physiol 2008; 102: 431-438.
91. Conley DL, Krahenbuhl GS. Running economy and distance running performance of highly trained athletes. Med Sci Sports Exerc 1980; 12: 357-360.
92. Saltin B, Kim CK, Terrados N, Larsen H, Svedenhag J, Rolf CJ. Morphology, enzyme activities and buffer capacity in leg muscles of Kenyan and Scandinavian runners. Scand J Med Sci Sports 1995; 5: 222-230.
93. Bassett DR Jr, Howley ET. Maximal oxygen uptake: 'classical' versus 'contemporary' viewpoints. Med Sci Sports Exerc 1997; 29: 591-603.
94. Coyle EF, Sidossis LS, Horowitz JF, Beltz JD. Cycling efficiency is related to the percentage of type I muscle fibers. Med Sci Sports Exerc 1992; 24: 782-788.
95. Horowitz JF, Sidossis LS, Coyle EF. High efficiency of type I muscle fibers improves performance. Int J Sports Med 1994; 15: 152-157.
96. Green HJ, Klug GA, Reichmann H, Seedorf U, Wiehrer W, Pette D. Exercise-induced fibre type transitions with regard to myosin, parvalbumin, and sarcoplasmic reticulum in muscles of the rat. Pflugers Arch 1984; 400: 432-438.
97. Tesch PA, Karlsson J. Muscle fiber types and size in trained and untrained muscles of elite athletes. J Appl Physiol 1985; 59: 1716-1720.
98. Longhurst JC, Kelly AR, Gonyea WJ, Mitchell JH. Cardiovascular responses to static exercise in distance runners and weight lifters. J Appl Physiol 1980; 49: 676-683.
99. Roskamm H. Optimum patterns of exercise for healthy adults. Can Med Assoc J 1967; 96: 895-900.
100. Lucia A, Carvajal A, Calderon FJ, Alfonso A, Chicharro JL. Breathing pattern in highly competitive cyclists during incremental exercise. Eur J Appl Physiol Occup Physiol 1999; 79: 512-521.
101. Coyle EF. Integration of the physiological factors determining endurance performance ability. Exerc Sport Sci Rev 1995; 23: 25-63.
102. Hawley JA, Noakes TD. Peak power output predicts maximal oxygen uptake and performance time in trained cyclists. Eur J Appl Physiol Occup Physiol 1992; 65: 79-83.
103. Swain DP. The influence of body mass in endurance bicycling. Med Sci Sports Exerc 1994; 26: 58-63.
104. Lundby C, Achman-Andersen NJ, Thomsen JJ, Norgaard AM, Robach P. Testing for recombinant human erythropoietin in urine: problems associated with current anti-doping testing. J Appl Physiol 2008; 105: 417-419.
105. Thomsen JJ, Rentsch RL, Robach P, Calbet JA, Boushel R, Rasmussen P, Juel C, Lundby C. Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity. Eur J Appl Physiol 2007; 101: 481-486.
106. Wilkerson DP, Rittweger J, Berger NJ, Naish PF, Jones AM. Influence of recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics during exercise in humans. J Physiol 2005; 568: 639-652.
107. Rasmussen P, Foged EM, Krogh-Madsen R, Nielsen J, Nielsen TR, Olsen NV, Petersen NC, Sorensen TA, Secher NH, Lundby C. Effects of erythropoietin administration on cerebral metabolism and exercise capacity in men. J Appl Physiol 2010; 109: 476-483.
108. Lundby C, Damsgaard R. Exercise performance in hypoxia after novel erythropoiesis stimulating protein treatment. Scand J Med Sci Sports 2006; 16: 35-40.
109. Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, Howe C, Martin DT, Trout GJ, Hahn AG. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 2000; 85: 564-572.
110. Russell G, Gore CJ, Ashenden MJ, Parisotto R, Hahn AG. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise 1. Eur J Appl Physiol 2002; 86: 442-449.
111. Connes P, Perrey S, Varray A, Prefaut C, Caillaud C. Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment. Pflugers Arch 2003; 447: 231-238.
112. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power. Scand J Med Sci Sports 1991; 1: 88-93.
113. Ninot G, Connes P, Caillaud C. Effects of recombinant human erythropoietin injections on physical self in endurance athletes 1. J Sports Sci 2006; 24: 383-391.
114. Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart MT, Marion B, Bressolle F. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc 1999; 31: 639-645.
115. Birkeland KI, Stray-Gundersen J, Hemmersbach P, Hallen J, Haug E, Bahr R. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc 2000; 32: 1238-1243.
116. Souillard A, Audran M, Bressolle F, Gareau R, Duvallet A, Chanal JL. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control. Br J Clin Pharmacol 1996; 42: 355-364.
117. Faria EW, Parker DL, Faria IE. The science of cycling: physiology and training - part 1. Sports Med 2005; 35: 285-312.
118. Hopkins WG, Hawley JA, Burke LM. Design and analysis of research on sport performance enhancement. Med Sci Sports Exerc 1999; 31: 472-485.
119. Eichner ER. Sports anemia, iron supplements, and blood doping. Med Sci Sports Exerc 1992; 24: S315-S318.
120. Schmidt W, Biermann B, Winchenbach P, Lison S, Boning D. How valid is the determination of hematocrit values to detect blood manipulations? Int J Sports Med 2000; 21: 133-138.
121. PIROFSKY B. The determination of blood viscosity in man by a method based on Poiseuille's law. J Clin Invest 1953; 32: 292-298.
122. Shand BI, Buttimore AL, Lynn KL, Bailey RR, Robson RA. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity. Ren Fail 1994; 16: 407-413.
123. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JA, Robach P. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 2007; 578: 309-314.
124. Lucia A, Rabadan M, Hoyos J, Hernandez-Capilla M, Perez M, San Juan AF, Earnest CP, Chicharro JL. Frequency of the VO2max plateau phenomenon in world-class cyclists. Int J Sports Med 2006; 27: 984-992.
125. Jeukendrup A, Saris WH, Brouns F, Kester AD. A new validated endurance performance test. Med Sci Sports Exerc 1996; 28: 266-270.
126. Krebs PS, Powers SK. Reliability of laboratory endurance tests. Med Sci Sports Exerc 1989; 21: S10.
127. Lucia A, Hoyos J, Santalla A, Earnest C, Chicharro JL. Tour de France versus Vuelta a Espana: which is harder? Med Sci Sports Exerc 2003; 35: 872-878.
128. Padilla S, Mujika I, Orbananos J, Angulo F. Exercise intensity during competition time trials in professional road cycling. Med Sci Sports Exerc 2000; 32: 850-856.
129. Lundby C, Robach P, Boushel R, Thomsen JJ, Rasmussen P, Koskolou M, Calbet JA. Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport? J Appl Physiol 2008; 105: 581-587.
130. Padilla S, Mujika I, Cuesta G, Goiriena JJ. Level ground and uphill cycling ability in professional road cycling. Med Sci Sports Exerc 1999; 31: 878-885.
131. Bentley DJ, McNaughton LR, Thompson D, Vleck VE, Batterham AM. Peak power output, the lactate threshold, and time trial performance in cyclists. Med Sci Sports Exerc 2001; 33: 2077-2081.
132. Hoogeveen AR, Hoogsteen GS. The ventilatory threshold, heart rate, and endurance performance: relationships in elite cyclists. Int J Sports Med 1999; 20: 114-117.
133. Lucia A, Hoyos J, Perez M, Santalla A, Earnest CP, Chicharro JL. Which laboratory variable is related with time trial performance time in the Tour de France? Br J Sports Med 2004; 38: 636-640.
134. Christensen B, Lundby C, Jessen N, Nielsen TS, Vestergaard PF, Moller N, Pilegaard H, Pedersen SB, Kopchick JJ, Jorgensen JO. Evaluation of functional erythropoietin receptor status in skeletal muscle in vivo: acute and prolonged studies in healthy human subjects. PLoS ONE 2012; 7: e31857.
135. Lundby C, Hellsten Y, Jensen MB, Munch AS, Pilegaard H. Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle. J Appl Physiol 2008; 104: 1154-1160.
136. Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, Pedersen BK, Gehl J. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS ONE 2009; 4: e5894.
137. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006; 70: 246-250.
138. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 2010; 29: 86-92.
139. Rathod DB, Salahudeen AK. Nonerythropoietic properties of erythropoietin: implication for tissue protection. J Investig Med 2011; 59: 1083-1085.
140. Vogel J, Gassmann M. Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models. J Physiol 2011; 589: 1259-1264.
141. Erbayraktar S, Yilmaz O, Gokmen N, Brines M. Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep 2003; 2: 465-470.
142. Patel NS, Collino M, Yaqoob MM, Thiemermann C. Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care 2011; 1: 40.
143. Hojman P, Taudorf S, Lundby C, Pedersen BK. Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine 2009; 45: 154-157.
144. Kuipers H. Doping in sport-exercise scientists have to take responsibility. Int J Sports Med 2001; 22: 545.
145. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004; 27: 185-190.
146. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965-976.
147. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Djulbegovic B, Bennett CL, Langensiepen S, Hyde C, Engert A. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: 708-714.
148. Stowell CP, Jones SC, Enny C, Langholff W, Leitz G. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine 2009; 34: 2479-2485.
149. Linde T, Sandhagen B, Danielson BG, Wikstrom B. Impaired erythrocyte fluidity during treatment of renal anaemia with erythropoietin. J Intern Med 1992; 231: 601-606.
150. Clyne N, Berglund B, Egberg N. Treatment with recombinant human erythropoietin induces a moderate rise in hematocrit and thrombin antithrombin in healthy subjects. Thromb Res 1995; 79: 125-129.
151. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983-2989.
152. Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, Fareed J. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 2004; 10: 225-232.
153. Sinzinger H, Virgolini I. Effects of exercise on parameters of blood coagulation, platelet function and the prostaglandin system. Sports Med 1988; 6: 238-245.
154. Gonzalez-Alonso J, Mora-Rodriguez R, Below PR, Coyle EF. Dehydration markedly impairs cardiovascular function in hyperthermic endurance athletes during exercise. J Appl Physiol 1997; 82: 1229-1236.
155. Gonzalez-Alonso J, Mora-Rodriguez R, Coyle EF. Stroke volume during exercise: interaction of environment and hydration. Am J Physiol Heart Circ Physiol 2000; 278: H321-H330.
156. Wade JP. Transport of oxygen to the brain in patients with elevated haematocrit values before and after venesection. Brain 1983; 106: (Pt 2): 513-523.
157. Lage JM, Panizo C, Masdeu J, Rocha E. Cyclist's doping associated with cerebral sinus thrombosis. Neurology 2002; 58: 665.
158. Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol 2000; 1: 11-31.
159. Burch GE, DePasquale NP. Hematocrit, blood viscosity and myocardial infarction. Am J Med 1962; 32: 161-163.
160. Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology 1997; 49: 686-689.
161. Cazzola M. Erythropoietin therapy: need for rationality and active surveillance. Haematologica 2003; 88: 601-605.
162. Casadevall N, Cournoyer D, Marsh J, Messner H, Pallister C, Parker-Williams J, Rossert J. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol 2004; 73: 389-396.
163. Smalling R, Foote M, Molineux G, Swanson SJ, Elliott S. Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge. Biotechnol Annu Rev 2004; 10: 237-250.
164. Fandrey J, Dicato M. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. Oncologist 2009; 14: (Suppl. 1): 34-42.